A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells.
Induction of the breast cancer resistance protein (BCRP/ABCG2) expression has been found in various tissues and cell-types after exposure to chemicals including 17β-estradiol, rosiglitazone, imatinib, as well as aryl hydrocarbon receptor (AhR) activators such as 2,3,7,8-tetrachlorodibenzodioxin, 3-methylcholanthrene (3MC), and omeprazole. However, the mechanism(s) underlying AhR-related induction of ABCG2 is largely unknown. Here, we demonstrate the AhR-dependent induction of ABCG2 expression in human colon adenocarcinoma LS174T cells. Importantly, a novel distal AhR-responsive element (AhRE5) located -2357/-2333bp upstream of the ABCG2 transcriptional start site has been identified and characterized as a functional unit pivotal to 3MC-mediated induction of ABCG2. Cell-based reporter assays revealed that deletion of AhRE5 and 4 dramatically attenuated 3MC-induced activation of ABCG2 reporter activity, while further deletion of the proximal AhRE3 and 2 only moderately changed the luciferase activities. Notably, site-directed mutation of the AhRE5 in the BCRP-3.8kb reporter construct alone resulted in approximately 80% decrease in 3MC activation of the ABCG2 promoter; additional mutation of the AhRE4 site had negligible effect on the ABCG2 promoter activity. Moreover, chromatin immunoprecipitation assays demonstrated that treatment with 3MC significantly enhanced the recruitment of AhR to the AhRE5 occupied region, and mutation of the AhRE5 site clearly dissociated AhR protein from this promoter region. Together, these data show that the novel distal AhRE5 is critical for AhR-mediated transcriptional activation of ABCG2 gene expression in LS174T cells, and it may offer new strategies for early identification of ABCG2 inducers, which would be of benefit for preventing transporter-associated drug-drug interactions.
Tompkins
Leslie M
LM
Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, United States.
Li
Haishan
H
Li
Linhao
L
Lynch
Caitlin
C
Xie
Yi
Y
Nakanishi
Takeo
T
Ross
Douglas D
DD
Wang
Hongbing
H
D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000096:biosynthesis* / Q000235:genetics; D051792:Basic Helix-Loop-Helix Proteins / Q000502:physiology*; D045744:Cell Line, Tumor; D055785:Gene Knockdown Techniques; D020441:Ginkgo biloba; D006801:Humans; D008748:Methylcholanthrene / Q000494:pharmacology; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D010936:Plant Extracts / Q000494:pharmacology; D018336:Receptors, Aryl Hydrocarbon / Q000502:physiology*; D020218:Response Elements / Q000187:drug effects / Q000502:physiology; D015533:Transcriptional Activation / Q000187:drug effects / Q000502:physiology; D015262:Xenobiotics / Q000494:pharmacology*; D000096983:Ginkgo Extract
D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; D051792:Basic Helix-Loop-Helix Proteins; D008748:Methylcholanthrene; D009363:Neoplasm Proteins; D010936:Plant Extracts; D018336:Receptors, Aryl Hydrocarbon; D015262:Xenobiotics; C116614:ABCG2 protein, human; C111235:AHR protein, human; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract
Cancer Res. 1998 Dec 15;58(24):5707-12
9865727
J Clin Oncol. 2002 Jul 1;20(13):2943-50
12089223
Toxicol Sci. 2009 Oct;111(2):238-46
19474220
Biochim Biophys Acta. 2001 Sep 21;1520(3):234-41
11566359
J Biol Chem. 2006 Aug 18;281(33):23812-23
16785230
Arch Biochem Biophys. 2000 Jan 1;373(1):163-74
10620335
Hepatology. 2001 May;33(5):1232-8
11343253
Toxicol Sci. 2007 Apr;96(2):227-36
17077187
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14138-43
9391166
Arch Biochem Biophys. 1998 Sep 1;357(1):155-63
9721195
J Biol Chem. 2003 Apr 25;278(17):15001-6
12566446
Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8185-9
1325649
Toxicol Appl Pharmacol. 2008 Jul 15;230(2):252-60
18433817
Mol Pharmacol. 1999 Oct;56(4):784-90
10496962
J Biol Chem. 2004 Jun 4;279(23):24218-25
15044468
Mol Pharmacol. 2010 Aug;78(2):175-85
20460431
Annu Rev Pharmacol Toxicol. 1995;35:307-40
7598497
Drug Metab Dispos. 2006 Oct;34(10):1756-63
16837569
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70
9861027
Cancer Res. 2001 Apr 15;61(8):3458-64
11309308
Mol Pharmacol. 1993 Apr;43(4):504-8
8386305
Biochem Biophys Res Commun. 2005 Jun 17;331(4):993-1000
15882976
Nat Rev Cancer. 2002 Jan;2(1):48-58
11902585
Cancer Res. 2005 Jan 15;65(2):596-604
15695404
Cancer Res. 2004 Feb 15;64(4):1247-51
14973083
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4150-5
12644700
Am J Physiol Endocrinol Metab. 2006 May;290(5):E798-807
16352672
Br J Pharmacol. 2007 May;151(2):163-74
17375082
Carcinogenesis. 2005 Oct;26(10):1754-63
15917307
Pharm Res. 2009 Apr;26(4):872-82
19034627
Curr Opin Pharmacol. 2006 Oct;6(5):528-32
16899406
Cancer Res. 2003 Jul 15;63(14):4048-54
12874005
Mol Pharm. 2009 Nov-Dec;6(6):1631-43
19874004
Curr Protein Pept Sci. 2002 Oct;3(5):503-11
12369998
Cancer Biol Ther. 2005 Jul;4(7):747-52
15970668
Stem Cells. 2002;20(1):11-20
11796918